Alexion Pharmaceuticals receives Japanese approval for blood disorder drug Soliris

Alexion’s Soliris approved in Japan

CHESHIRE, Conn. — Alexion Pharmaceuticals Inc. said Friday its blood disorder treatment had received regulatory approval in Japan.

Soliris, approved by Japan’s Ministry of Health, Labour and Welfare, treats a rare chronic disease called paroxysmal nocturnal hemoglobinuria, which causes a breakdown of red blood cells and leads to anemia.

The drug is already approved in the U.S. and Europe.